Annovis Bio Inc. (ANVS) is gaining attention as it advances multiple late-stage clinical programs targeting neurodegenerative diseases. With its lead candidate Buntanetap progressing through pivotal trials in Alzheimer's disease (AD) and Parkinson's disease (PD), and a scheduled FDA Type C meeting in January 2026 to discuss the pathway for Parkinson's disease dementia (PDD), the company is positioned for several catalysts that could reshape its outlook in the coming year.
Recent Stock Performance
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com